Clinical trials: Anti-PD1 Antibody
Melanoma (Skin)
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
The purpose of this study is to test the side effects of an investigational vaccine with an immune booster, or 2 different boosters together.
- Trial name
- NCT01176474
- Testing
- NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sarcoma
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure.
- Trial name
- NCT04126993
- Testing
- Camrelizumab,, Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extranodal Natural Killer T Cell Lymphoma
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in…
- Trial name
- NCT06255795
- Testing
- chidamide, anti-PD1 antibody, and pegaspargase, DDGP
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Ruijin Hospital
Esophageal Neoplasms
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced…
- Trial name
- AIPAAIAEC (NCT05349045)
- Testing
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Melanoma (Skin)
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine.
- Trial name
- NCT01176461
- Testing
- MART-1, NY-ESO-1, gp100:209-217(210M)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT05608291
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,564 people
- Sponsor
- Regeneron Pharmaceuticals
B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Tisagenlecleucel (CTL019) is an anti-CD19 autologous Chimeric Antigen Receptor (CAR) T-cell therapy, which has shown dramatic early results in advanced ALLs.
- Trial name
- CAPTiRALL (NCT05310591)
- Testing
- Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1
- Where
- 13 sites in France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody and P-GemOx in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573151
- Testing
- Selinexor, anti-PD-1 antibody and P-GemOx
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
DIPG
Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma
Diffuse pontine gliomas are incurable with currently used treatments. based on data stating that progressive tumors inhibit immune system, would try to enhance immune system activity and tumor cell killing.
- Trial name
- NCT01952769
- Testing
- MDV9300
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin…
- Trial name
- NCT04514081
- Testing
- Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Soft Tissue Sarcoma, Bone Sarcoma
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
- Trial name
- NCT02301039
- Testing
- Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 144 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Chordoma, Locally Advanced Chordoma
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body.
- Conditions
- Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
- Trial name
- NCT03623854
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Relapsed or Refractory Classical Hodgkin Lymphoma
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
- Trial name
- NCT05216835
- Testing
- Sabestomig (AZD7789)
- Where
- 14 sites in United States, Canada and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Neoplasms by Site
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or…
- Trial name
- NCT01968109
- Testing
- Relatlimab, Nivolumab, BMS-986213
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 1,482 people
- Sponsor
- Bristol-Myers Squibb
Thyroid Cancer
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
- Trial name
- NCT04612894
- Testing
- Camrelizumab and Apatinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Early Melanoma, Advanced Melanoma
Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or…
- Trial name
- MELCAYA (NCT06281912)
- Where
- 13 sites in France, Germany and 5 more
- Volunteers
- 70 people
- Sponsor
- Azienda Ospedaliera di Perugia
Malignancies Multiple
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including…
- Trial name
- NCT02961101
- Testing
- Anti-PD-1 antibody, Decitabine, Chemotherapy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Han weidong